Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Matrix Protein 1 (M1 or M) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Matrix Protein 1 (M1 or M) Products under Development by Stage of Development | 7 | 1 |
| Matrix Protein 1 (M1 or M) Products under Development by Therapy Area | 8 | 1 |
| Matrix Protein 1 (M1 or M) Products under Development by Indication | 9 | 1 |
| Matrix Protein 1 (M1 or M) Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Unknown Stage Products | 12 | 1 |
| Matrix Protein 1 (M1 or M) Products under Development by Companies | 13 | 2 |
| Matrix Protein 1 (M1 or M) Products under Development by Universities/Institutes | 15 | 2 |
| Matrix Protein 1 (M1 or M) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Matrix Protein 1 (M1 or M) Companies Involved in Therapeutics Development | 23 | 3 |
| Novavax, Inc. | 23 | 1 |
| Redbiotec AG | 24 | 1 |
| Sarepta Therapeutics, Inc. | 25 | 1 |
| Matrix Protein 1 (M1 or M) Drug Profiles | 26 | 10 |
| (influenza (virus like particle) + respiratory syncytial virus) vaccine Drug Profile | 26 | 1 |
| influenza (virus like particle) vaccine Drug Profile | 27 | 1 |
| influenza (virus like particle, tetravalent) vaccine Drug Profile | 28 | 2 |
| influenza [serotype A] vaccine Drug Profile | 30 | 1 |
| influenza [strain A/H7N9] (virus like particle, monovalent) vaccine Drug Profile | 31 | 2 |
| radavirsen Drug Profile | 33 | 2 |
| SARS (virus like particle) vaccine Drug Profile | 35 | 1 |
| Matrix Protein 1 (M1 or M) Featured News &Press Releases | 36 | 10 |
| Jul 30, 2015: Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP | 36 | 1 |
| Nov 17, 2014: Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP | 36 | 1 |
| Oct 29, 2014: U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M | 37 | 1 |
| Sep 30, 2014: Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate | 38 | 1 |
| Sep 23, 2014: Novavax H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M Delivers Positive Phase 1/2 Clinical Data | 38 | 1 |
| Mar 10, 2014: Novavax Reports Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M | 39 | 1 |
| Jul 29, 2013: Novavax Initiates First Phase 1 Clinical Trial of its A Influenza Vaccine Candidate | 39 | 1 |
| Jul 08, 2013: GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine | 40 | 1 |
| Jul 08, 2013: Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate | 40 | 1 |
| May 10, 2013: Novavax's H7N9 VLP Influenza Vaccine Enters Animal Testing | 41 | 1 |
| Feb 27, 2013: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA | 41 | 1 |
| Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 | 42 | 1 |
| Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine | 43 | 1 |
| Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs | 44 | 1 |
| Mar 30, 2012: AVI BioPharma To Present Preclinical Data From Influenza Study At 22nd European Congress Of Clinical Microbiology And Infectious Diseases | 45 | 1 |
| Appendix | 46 | 2 |
| Methodology | 46 | 1 |
| Coverage | 46 | 1 |
| Secondary Research | 46 | 1 |
| Primary Research | 46 | 1 |
| Expert Panel Validation | 46 | 1 |
| Contact Us | 46 | 1 |
| Disclaimer | 47 | 1 |